Kolon TissueGene, Inc. Logo

Kolon TissueGene, Inc.

Developing cell and gene therapies for orthopedic and degenerative disorders.

950160 | KO

Overview

Corporate Details

ISIN(s):
KR8840120008
LEI:
Country:
United States of America
Address:
9713 Key West Ave Suite 300, Rockville
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Kolon TissueGene, Inc. is a clinical-stage biopharmaceutical company specializing in the development of advanced cell and gene therapies for orthopedic and degenerative disorders. The company's lead product candidate, TG-C, is a first-in-class, disease-modifying allogeneic cell therapy for the treatment of knee osteoarthritis. This innovative therapy is designed to reduce pain, improve joint function, and potentially slow disease progression. Kolon TissueGene is advancing TG-C through late-stage clinical trials and exploring the application of its platform technology for other degenerative conditions, such as spinal diseases.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-12 00:00
Capital/Financing Update
주요사항보고서(전환사채권발행결정)
Korean 88.5 KB
2025-09-11 00:00
Legal Proceedings Report
[기재정정]소송등의제기ㆍ신청(일정금액이상의청구)
Korean 20.0 KB
2025-09-10 00:00
Legal Proceedings Report
[기재정정]소송등의제기ㆍ신청(일정금액이상의청구)
Korean 13.9 KB
2025-09-09 00:00
Legal Proceedings Report
[기재정정]소송등의제기ㆍ신청(일정금액이상의청구)
Korean 19.1 KB
2025-09-04 00:00
Legal Proceedings Report
[기재정정]소송등의제기ㆍ신청(일정금액이상의청구)
Korean 18.6 KB
2025-08-27 00:00
Legal Proceedings Report
[기재정정]소송등의제기ㆍ신청(일정금액이상의청구)
Korean 18.7 KB
2025-08-14 00:00
Capital/Financing Update
파생상품거래손실발생
Korean 7.8 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.3 MB
2025-07-28 00:00
Share Issue/Capital Change
[기재정정]전환청구권행사
Korean 13.1 KB
2025-07-24 00:00
Legal Proceedings Report
[기재정정]소송등의제기ㆍ신청(일정금액이상의청구)
Korean 20.3 KB
2025-07-22 00:00
Legal Proceedings Report
[기재정정]소송등의제기ㆍ신청(일정금액이상의청구)
Korean 16.7 KB
2025-07-14 00:00
Regulatory News Service
[기재정정]투자판단관련주요경영사항 (기술수출 계약 체결(당사의 라이센시인 코오롱생명과학㈜ 주요경영사항))
Korean 17.9 KB
2025-07-11 00:00
Share Issue/Capital Change
[기재정정]전환청구권행사 (제2회차)
Korean 11.8 KB
2025-07-10 00:00
Legal Proceedings Report
[기재정정]소송등의제기ㆍ신청(일정금액이상의청구)
Korean 16.2 KB
2025-07-10 00:00
Share Issue/Capital Change
전환청구권행사 (제2회차)
Korean 8.7 KB

Automate Your Workflow. Get a real-time feed of all Kolon TissueGene, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Kolon TissueGene, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Kolon TissueGene, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Aprogen, Inc Logo
Develops and manufactures novel biologics and biosimilars for cancer and arthritis treatments.
South Korea
007460
Develops drugs for fibrosis, inflammation, and cancer using NOX inhibitor & CAF modulation tech.
South Korea
293780
Aptahem AB Logo
Develops RNA aptamers to treat acute, life-threatening conditions like sepsis.
Sweden
APTA
Aptamer Sciences Inc Logo
Develops aptamer-based therapeutics and diagnostics for oncology and solid tumors.
South Korea
291650
Aptevo Therapeutics Inc. Logo
Developing multi-specific antibody immunotherapies for hematologic and solid tumor cancers.
United States of America
APVO
Aptorum Group Ltd Logo
Biopharma developing novel therapeutics for oncology, infectious and metabolic diseases.
United States of America
APM
Aquestive Therapeutics, Inc. Logo
Develops oral film drugs for CNS disorders and severe allergies.
United States of America
AQST
Arbutus Biopharma Corp Logo
A clinical-stage virology company developing a functional cure for chronic hepatitis B (HBV).
United States of America
ABUS
Arcellx, Inc. Logo
Engineering controllable cell therapies for cancer and autoimmune diseases.
United States of America
ACLX
Arctic Bioscience Logo
Develops pharma & nutra ingredients from marine lipids for autoimmune & wellness applications.
Norway
ABS

Talk to a Data Expert

Have a question? We'll get back to you promptly.